NCT04599192

Brief Summary

A real world study to evaluate outcomes in women based on guideline identified fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) cutoffs for ischemia (ischemia defined as FFR ≤ 0.80 and iFR ≤ 0.89).

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
36mo left

Started Apr 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress70%
Apr 2019Apr 2029

Study Start

First participant enrolled

April 19, 2019

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

August 12, 2020

Completed
2 months until next milestone

First Posted

Study publicly available on registry

October 22, 2020

Completed
5.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 10, 2026

Completed
3.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2029

Expected
Last Updated

November 5, 2025

Status Verified

November 1, 2025

Enrollment Period

7 years

First QC Date

August 12, 2020

Last Update Submit

November 3, 2025

Conditions

Keywords

WOMEN FiRSTFFR in WomeniFR in Women

Outcome Measures

Primary Outcomes (4)

  • Repeat revascularization

    Repeat revascularizations will be documented throughout the course of the 5 year follow up period

    5 years

  • Non-fatal myocardial infarction

    Non-fatal myocardial infarctions will be documented throughout the course of the 5 year follow up period

    5 years

  • Non-fatal stroke

    Non-fatal strokes will be documented throughout the course of the 5 year follow up period

    5 years

  • Cardiovascular death

    Cardiovascular related death will be documented throughout the course of the 5 year follow up period

    5 years

Study Arms (1)

Women Presenting with Cardiac Ischemia

Women presenting with cardiac ischemia as indicated by standard of care non-invasive stress testing with cardiac magnetic resonance (CMR), SPECT myocardial perfusion, and PET myocardial perfusion imaging. This cohort of women must also meet the clinical criteria to undergo coronary angiography. Women may be approached for consent either before or after their coronary angiography procedure.

Other: No study intervention

Interventions

The study does not determine any interventions. Any intervention performed during coronary angiography is considered standard of care.

Women Presenting with Cardiac Ischemia

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsParticipant eligibility is not based on self-representation of gender identity
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult female patients (\>18 years of age) presenting with suspected myocardial ischemia or acute coronary syndrome for evaluation of ischemia by non-invasive stress testing and coronary angiography.

You may qualify if:

  • Female ≥ 18 years old at signing of informed consent
  • Suspected myocardial ischemia or acute coronary syndrome
  • Indication for non-invasive perfusion imaging study
  • Indication for diagnostic catheterization
  • Eligible for PCI
  • Signed informed clinical procedural consent by subject or by surrogate

You may not qualify if:

  • Inability to receive adenosine or regadenoson (for example, severe reactive airway disease, marked hypotension, or advanced atrioventricular block without pacemaker.
  • Severe cardiomyopathy (ejection fraction \<30%)
  • Extremely tortuous or calcified coronary arteries precluding FFR/iFR measurements
  • Patients with left main coronary artery disease requiring revascularization
  • Female of child baring age should have negative pregnancy test
  • Subject is pregnant or breast feeding, or planning to become pregnant
  • Contraindication to non-invasive stress imaging including severe claustrophobia, renal disease with GFR \<30 where CMR is indication, any metal in the body which is a contraindication to CMR, allergy to gadolinium contrast
  • ICD or PPM

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yale University School of Medicine - Section of Cardiology

New Haven, Connecticut, 06520, United States

Location

Related Publications (2)

  • Gitto, M., Saito Y., Schneider, M., Papoutsidakis, N., Ardito, S., McCarthy, M., Cristea, E., Lansky, A., Altin, E. (2020). Journal of the American College of Cardiology. Discrepancy Between Visually Assessed and Quantitative Coronary Angiography Derived Diameter Stenosis in a Cohort of Women with Stable Coronary Artery Disease, 75(11). https://www.onlinejacc.org/content/75/11_Supplement_1/178

    BACKGROUND
  • Gitto, M., Saito Y., Schneider, M., Papoutsidakis, N., Ardito, S., McCarthy, M., Cristea, E., Lansky, A., Altin, E. (2020). Journal of the American College of Cardiology. Quantitative Flow Ratio According to Three-Dimensional Quantitative Coronary Angiography Defined Severity of Stenosis in a Cohort of Women with Stable Coronary Artery Disease, 75(11). https://www.onlinejacc.org/content/75/11_Supplement_1/177

    BACKGROUND

MeSH Terms

Conditions

Coronary Disease

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Study Officials

  • Elissa Altin, MD

    Yale University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 12, 2020

First Posted

October 22, 2020

Study Start

April 19, 2019

Primary Completion

April 10, 2026

Study Completion (Estimated)

April 30, 2029

Last Updated

November 5, 2025

Record last verified: 2025-11

Locations